Posicionamento sobre Segurança Cardiovascular das Vacinas contra COVID-19 - 2022

Liga de Hipertensão Arterial Universidade Federal de Goiás,1 Goiânia, GO – Brasil Hospital Israelita Albert Einstein,2 São Paulo, SP – Brasil Centro de Infusão e Hospital Dia do InCor,3 São Paulo, SP – Brasil Faculdade de Medicina da Universidade de São Paulo (FMUSP),4 São Paulo, SP – Brasil Departamento de Insuficiência Cardíaca da Sociedade Brasileira de Cardiologia (DEIC) Diretoria 2022-2023,5 Rio de Janeiro, RJ – Brasil Projeto Insuficiência Cardíaca da Sociedade de Cardiologia do Estado de São Paulo (SOCESP),6 São Paulo, SP – Brasil Rede D’Or,7 Rio de Janeiro, RJ – Brasil Instituto Dante Pazzanese de Cardiologia,8 São Paulo, SP – Brasil Biocor Instituto,9 Nova Lima, MG – Brasil Programa de Pós-graduação em Cardiologia da Universidade Federal do Rio Grande do Sul,10 Porto Alegre, RS – Brasil Hospital de Clínicas de Porto Alegre,11 Porto Alegre, RS – Brasil Instituto Nacional de Avaliação de Tecnologia em Saúde,12 Porto Alegre, RS – Brasil Hospital Moinhos de Vento,13 Porto Alegre, RS – Brasil

[1]  Jennifer Abbasí.  The COVID Heart-One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks. , 2022, JAMA.

[2]  Matthew W. Martinez,et al.  2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play , 2022, Journal of the American College of Cardiology.

[3]  Manfred S. Green,et al.  Myocarditis after BNT162b2 Vaccination in Israeli Adolescents , 2022, The New England journal of medicine.

[4]  Michael John Smith,et al.  Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. , 2022, JAMA.

[5]  William F. Fadel,et al.  Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[6]  Melissa G. Pike,et al.  COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 , 2022, MMWR. Morbidity and mortality weekly report.

[7]  T. Ortel,et al.  Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination—United States, December 2020 to August 2021 , 2022, Annals of Internal Medicine.

[8]  A. Randolph,et al.  Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021 , 2022, MMWR. Morbidity and mortality weekly report.

[9]  K. Khunti,et al.  Risk of myocarditis following sequential COVID-19 vaccinations by age and sex , 2021, medRxiv.

[10]  H. Sørensen,et al.  SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study , 2021, BMJ.

[11]  K. Khunti,et al.  Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection , 2021, Nature Medicine.

[12]  Manfred S. Green,et al.  Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel , 2021, The New England journal of medicine.

[13]  R. Balicer,et al.  Myocarditis after Covid-19 Vaccination in a Large Health Care Organization , 2021, The New England journal of medicine.

[14]  Bruno Lewin,et al.  Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. , 2021, JAMA internal medicine.

[15]  J. Nelson,et al.  Surveillance for Adverse Events After COVID-19 mRNA Vaccination. , 2021, JAMA.

[16]  G. Ambler,et al.  Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis , 2021, The New England journal of medicine.

[17]  H. Mullerova,et al.  Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis , 2021, The Lancet.

[18]  J. Gargano,et al.  Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[19]  G. Greil,et al.  Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age , 2021, The Journal of Pediatrics.

[20]  R. Kim,et al.  Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. , 2021, JAMA cardiology.

[21]  L. Cooper,et al.  Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. , 2021, JAMA cardiology.

[22]  H. Krumholz,et al.  Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19 , 2021, Journal of the American College of Cardiology.

[23]  Manish M Patel,et al.  Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2 , 2021, JAMA network open.

[24]  W. Ageno,et al.  SARS-CoV-2 vaccine and thrombosis: Expert opinions. , 2021, Thrombosis and haemostasis.

[25]  E. Woo,et al.  US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. , 2021, JAMA.

[26]  D. Goldblatt,et al.  Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination , 2021, The New England journal of medicine.

[27]  S. Koepsell,et al.  Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination , 2021, The New England journal of medicine.

[28]  Fridtjof Lund-Johansen,et al.  Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination , 2021, The New England journal of medicine.

[29]  Andreas Greinacher,et al.  Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.

[30]  Elisabeth Mahase.  AstraZeneca vaccine: Blood clots are “extremely rare” and benefits outweigh risks, regulators conclude , 2021, BMJ.

[31]  M. McNeil,et al.  Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018. , 2021, Vaccine.

[32]  S. Nopp,et al.  Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis , 2020, Research and Practice in Thrombosis and Haemostasis.

[33]  H. Ten Have,et al.  Vaccination , 1931, Journal of Cancer Research and Clinical Oncology.

[34]  OUP accepted manuscript , 2021, Clinical Infectious Diseases.

[35]  R. Evans.  European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).